About 308 results

ALLMedicine™ Alveolar Soft Part Sarcoma Center

Research & Reviews  109 results

Brain Metastasis in Soft Tissue Sarcoma at Initial Presentation.
Anticancer Research; Itoga R, Matsuoka M et. al.

Nov 5th, 2021 - Brain metastasis is a rare condition among patients with soft tissue sarcoma (STS), and its precise incidence remains unclear. The aim of this study was to investigate which patients should be screened for brain metastasis. We identified all patie...

Stereotactic radiosurgery in alveolar soft part sarcoma brain metastases: Case series a...
Journal of Clinical Neuroscience : Official Journal of Th... Lim JX, Karlsson B et. al.

Oct 18th, 2021 - Alveolar soft part sarcoma (ASPS) has the highest incidence of brain metastasis amongst sarcomas. There is a paucity of literature published focusing on radiation therapy for this condition. This is a single centre retrospective review of the trea...

Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical reco...
Cancer Treatment Reviews; Martínez-Trufero J, Cruz Jurado J et. al.

Aug 3rd, 2021 - Among all Soft Tissue sarcomas there are some subtypes with low incidence and/or peculiar clinical behaviour, that need to be consider separately. Most of them are orphan diseases, whose biological characteristics imply a clearly different diagnos...

Advances in the management of alveolar soft part sarcoma.
Current Problems in Cancer; O'Sullivan Coyne G, Naqash AR et. al.

Jul 22nd, 2021 - Alveolar Soft Part Sarcoma is one of the less commonly diagnosed soft tissue sarcoma subtypes, an infrequent subtype within the already rare category of human malignancy of sarcoma. In this article we will summarize the histopathological features,...

see more →

Clinicaltrials.gov  4 results

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Apr 27th, 2021 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma

Feb 12th, 2021 - Background and introduction Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism, although some limitations have been identified [1,2] Recently Fang and c...

Phase 2 Study in Patients With MiT Tumors

Feb 8th, 2013 - This is a multi-center, single arm, two-stage phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. ARQ 197 is a novel small molecule drug designed to block the activity of c-Met, which is thought t...

see more →

News  10 results

Dr. Trent on Research Efforts in Bone and Soft Tissue Sarcomas

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research efforts in bone and soft tissue sarcomas. Recently, several adv...

Chordomas: Rare, Indolent and Linked With Poor Outcomes, But Research Efforts Continue

Jul 29th, 2021 - Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull. It is the most common tumor of the sacrum and cervical spine, accounting for about 3% of all bone tumors and about 20% of primary spinal ...

TRK Fusion Inhibitors in Clinical Practice

Apr 28th, 2021 - Mark Socinski, MD: Dr Patel, you I think said early on that you had a handful of these patients with NTRK fusion-positive lung cancer. I wonder if you could tell us about your experience. Jyoti Patel, MD, FASCO: Primarily, I am prescribing more...

Immunotherapy Agents Emerging as Key Players in Sarcoma

Dec 20th, 2020 - Breelyn Wilky, MD Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD. In November, The European Commission granted an accelerated approval to olar...

Pembrolizumab Prolongs PFS in Rare Sarcoma Subtypes

Dec 20th, 2020 - Data from the sarcoma cohort of the phase 2 AcSé basket study presented during the 2020 ESMO Virtual Congress showed that pembrolizumab (Keytruda) monotherapy prolonged progression-free survival (PFS) in selected rare sarcoma subtypes, supporting ...

see more →